Menu
WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis
ST. LOUIS, Nov. 13, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington…
Read More